{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:06:57Z","timestamp":1785326817893,"version":"3.55.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cpet.2026.06.005","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:31:34Z","timestamp":1785324694000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[18F]FDG-PET in Lung Cancer: From Staging to Therapy Response"],"prefix":"10.1016","author":[{"given":"Harmandeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2026.06.005_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cpet.2026.06.005_bib2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cpet.2026.06.005_bib3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.21037\/tlcr-24-979","article-title":"Recent advancements in lung cancer research: a narrative review","volume":"14","author":"Tang","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cpet.2026.06.005_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12885-022-09421-7","article-title":"Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer\u2014is there a \u201ctail plateau\u201d in the survival curve of these patients?","volume":"22","author":"Shimamura","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cpet.2026.06.005_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cpet.2026.06.005_bib6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/modpathol.2010.111","article-title":"Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers","volume":"23","author":"Xing","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cpet.2026.06.005_bib7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib8","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Zer","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib9","author":"Aisner"},{"key":"10.1016\/j.cpet.2026.06.005_bib10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","article-title":"Global variations in lung cancer incidence by histological subtype in 2020: a population-based study","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib11","article-title":"The pivotal role of pathology in the management of lung cancer","volume":"5","author":"Davidson","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.cpet.2026.06.005_bib12","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1200\/JCO.2010.28.8126","article-title":"The evolving role of histology in the management of advanced non - small-cell lung cancer","volume":"28","author":"Langer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1126\/science.6695174","article-title":"Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient","volume":"223","author":"Santos","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.cpet.2026.06.005_bib14","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of Non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cpet.2026.06.005_bib16","doi-asserted-by":"crossref","first-page":"62ra93","DOI":"10.1126\/scitranslmed.3001451","article-title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","volume":"2","author":"Weiss","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0720-048X(02)00297-8","article-title":"The solitary pulmonary nodule","volume":"45","author":"Tang","year":"2003","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cpet.2026.06.005_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1148\/radiol.2017161659","article-title":"Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017","volume":"284","author":"MacMahon","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.cpet.2026.06.005_bib19","article-title":"Associations between the standardized uptake value of 18F-FDG PET\/CT and demographic, clinical, pathological, radiological factors in lung cancer","volume":"8","author":"Sunnetcioglu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41824-024-00187-8","article-title":"Diagnostic value of FDG PET-CT in differentiating lung adenocarcinoma from squamous cell carcinoma","volume":"8","author":"Maman","year":"2024","journal-title":"EJNMMI Rep"},{"key":"10.1016\/j.cpet.2026.06.005_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.acra.2020.01.030","article-title":"SUVmax of 18FDG PET\/CT predicts histological grade of lung adenocarcinoma","volume":"28","author":"Sun","year":"2021","journal-title":"Acad Radiol"},{"key":"10.1016\/j.cpet.2026.06.005_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-025-03430-3","article-title":"18F-FDG PET\/CT for prediction of PD-L1 expression and tumor mutational burden in non-small cell lung cancer: biomarkers prediction models development and immunotherapy responses verification","volume":"27","author":"Zhang","year":"2025","journal-title":"Respir Res"},{"key":"10.1016\/j.cpet.2026.06.005_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/2278-330X.114148","article-title":"Positron emission tomography-computed tomography in the management of lung cancer: an update","volume":"2","author":"Sharma","year":"2013","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.cpet.2026.06.005_bib24","doi-asserted-by":"crossref","first-page":"9370","DOI":"10.1038\/s41598-017-08764-7","article-title":"Diagnostic classification of solitary pulmonary nodules using dual time 18F-FDG PET\/CT image texture features in granuloma-endemic regions","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpet.2026.06.005_bib25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.crad.2019.04.024","article-title":"Comparison of 18F-FDG avidity at PET of benign and malignant pure ground-glass opacities: a paradox? Part II: artificial neural network integration of the PET\/CT characteristics of ground-glass opacities to predict their likelihood of malignancy","volume":"74","author":"Scott","year":"2019","journal-title":"Clin Radiol"},{"key":"10.1016\/j.cpet.2026.06.005_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2019.108735","article-title":"Potential feature exploration and model development based on 18F-FDG PET\/CT images for differentiating benign and malignant lung lesions","volume":"121","author":"Zhang","year":"2019","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cpet.2026.06.005_bib27","article-title":"PET\/CT-aided biopsy of lung lesions enhances diagnostic efficacy, especially for lesions >3cm","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib28","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170258","article-title":"Real-time intraprocedural 18F-FDG PET\/CT-guided biopsy using automated robopsy arm (ARA) in the diagnostic evaluation of thoracic lesions with prior inconclusive biopsy results: initial experience from a tertiary health care centre","volume":"90","author":"Radhakrishnan","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.cpet.2026.06.005_bib29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13139-020-00655-6","article-title":"Real time F-18 FDG PET-CT-Guided metabolic biopsy targeting differential FDG avidity in a pulmonary blastoma","volume":"54","author":"Jain","year":"2020","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2026.06.005_bib30","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2214\/AJR.10.4980","article-title":"Non\u2013small cell lung carcinoma: accuracy of PET\/CT in determining the size of T1 and T2 primary tumors","volume":"196","author":"Pawaroo","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.cpet.2026.06.005_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4185835","article-title":"Cloud-based lung tumor detection and stage classification using deep learning techniques","volume":"2022","author":"Kasinathan","year":"2022","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.cpet.2026.06.005_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1029684","article-title":"Predictive value of baseline metabolic tumor burden on 18F-FDG PET\/CT for brain metastases in patients with locally advanced non-small-cell lung cancer","volume":"12","author":"Shang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s40644-024-00811-7","article-title":"Prognostic value of metabolic tumor volume on [18F]FDG PET\/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer","volume":"24","author":"Brose","year":"2024","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.cpet.2026.06.005_bib34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21873\/cgp.20319","article-title":"Combination of circulating tumour DNA and 18F-FDG PET\/CT for precision monitoring of therapy response in patients with advanced non-small cell lung cancer: a prospective study","volume":"19","author":"Fiala","year":"2022","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.cpet.2026.06.005_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1634\/theoncologist.2010-0300","article-title":"Role of 18F-Fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer","volume":"16","author":"Mak","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.cpet.2026.06.005_bib36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13139-012-0142-z","article-title":"Correlation between 18F-Fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in advanced lung cancer","volume":"46","author":"Choi","year":"2012","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2026.06.005_bib37","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1038\/s41467-020-19116-x","article-title":"Non-invasive decision support for NSCLC treatment using PET\/CT radiomics","volume":"11","author":"Mu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpet.2026.06.005_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0846537119899526","article-title":"Radiogenomic models using machine learning techniques to predict EGFR mutations in non-small cell lung cancer","volume":"72","author":"Nair","year":"2021","journal-title":"Can Assoc Radiol J"},{"key":"10.1016\/j.cpet.2026.06.005_bib39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.21037\/tlcr.2020.04.17","article-title":"Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET\/CT radiomic features","volume":"9","author":"Liu","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cpet.2026.06.005_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.radonc.2008.11.008","article-title":"Use of PET and PET\/CT for radiation therapy planning: IAEA expert report 2006\u20132007","volume":"91","author":"MacManus","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040814","article-title":"FDG-PET radiomics for response monitoring in non-small-cell lung cancer treated with radiation therapy","volume":"13","author":"Carles","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cpet.2026.06.005_bib42","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2967\/jnumed.119.228106","article-title":"Pretreatment 18F-FDG PET\/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non\u2013small cell lung cancer: a multicentric study","volume":"61","author":"Dissaux","year":"2020","journal-title":"J Nuc Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/acm2.13696","article-title":"Potential advantages of FDG-PET radiomic feature map for target volume delineation in lung cancer radiotherapy","volume":"23","author":"Falahatpour","year":"2022","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.cpet.2026.06.005_bib44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13193-025-02322-8","article-title":"AI-Enhanced 4D CT radiotherapy planning for personalized lung cancer treatment with respiratory motion management","volume":"17","author":"Trabelsi","year":"2026","journal-title":"Indian J Surg Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221143224","article-title":"Machine learning radiomics model for external and internal respiratory motion correlation prediction in lung tumor","volume":"21","author":"Zhang","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.cpet.2026.06.005_bib46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cpet.2026.06.005_bib47","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nuc Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib48","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00259-019-04421-5","article-title":"Introducing FDG PET\/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial","volume":"46","author":"Konert","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2026.06.005_bib49","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.24.00022","article-title":"Primary results of NRG-RTOG1106\/ECOG-ACRIN 6697: a randomized phase II trial of individualized adaptive (chemo)Radiotherapy using midtreatment 18F-Fluorodeoxyglucose positron emission tomography\/computed tomography in stage III non-small cell lung cancer","volume":"42","author":"Kong","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib50","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2967\/jnumed.117.193003","article-title":"18F-FDG PET\/CT for very early response evaluation predicts CT response in erlotinib-treated non\u2013small cell lung cancer patients: a comparison of assessment methods","volume":"58","author":"Fledelius","year":"2017","journal-title":"J Nuc Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4274\/mirt.galenos.2022.24650","article-title":"The prognostic value of 18F-FDG PET\/CT metabolic parameters in predicting treatment response before EGFR TKI treatment in patients with advanced lung adenocarcinoma","volume":"31","author":"Ag\u00fclo\u011flu","year":"2022","journal-title":"Mol Imaging Radionucl Ther"},{"key":"10.1016\/j.cpet.2026.06.005_bib52","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/JTO.0b013e318219aac5","article-title":"Radiological changes after stereotactic radiotherapy for stage I lung cancer","volume":"6","author":"Dahele","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib53","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.semnuclmed.2022.06.001","article-title":"Response evaluation following radiation therapy with 18F-FDG PET\/CT: common variants of radiation-induced changes and potential pitfalls","volume":"52","author":"Dejanovic","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib54","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220339","article-title":"The lung cancers: staging and response, CT,18F-FDG PET\/CT, MRI, DWI: review and new perspectives","volume":"96","author":"Owens","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1016\/j.cpet.2026.06.005_bib55","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Robert","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib56","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","article-title":"Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0","volume":"49","author":"Lopci","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2026.06.005_bib57","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","article-title":"FDG PET\/CT for assessing tumour response to immunotherapy","volume":"46","author":"Aide","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2026.06.005_bib58","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2026.06.005_bib59","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","author":"Nishino","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2026.06.005_bib60","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpet.2026.06.005_bib61","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","article-title":"Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET\/CT imaging in patients with advanced melanoma","volume":"58","author":"Cho","year":"2017","journal-title":"J Nuc Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib62","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00259-018-3972-9","article-title":"The role of interim 18F-FDG PET\/CT in prediction of response to ipilimumab treatment in metastatic melanoma","volume":"45","author":"Sachpekidis","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2026.06.005_bib63","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2967\/jnumed.118.213652","article-title":"18F-FDG PET\/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma","volume":"60","author":"Ito","year":"2019","journal-title":"J Nuc Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","article-title":"Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST","volume":"9","author":"Goldfarb","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.cpet.2026.06.005_bib65","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","article-title":"Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET\/CT","volume":"44","author":"Nobashi","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib66","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.cllc.2025.11.011","article-title":"Diagnostic accuracy of [18F]FDG PET\/CT versus CT for NSCLC surveillance: secondary analysis of a randomized clinical trial","volume":"27","author":"Guldbrandsen","year":"2026","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cpet.2026.06.005_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0345990","article-title":"PRognostic and predictive potential of multiparametric dynamic whole-body 18F-FDG PET imaging using a long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol","volume":"21","author":"Geier","year":"2026","journal-title":"PLoS One"},{"key":"10.1016\/j.cpet.2026.06.005_bib68","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","article-title":"Molecular cloning of fibroblast activation protein \u03b1, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers","volume":"91","author":"Scanlan","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cpet.2026.06.005_bib69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2967\/jnumed.124.269002","article-title":"SNMMI procedure Standard\/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET","volume":"66","author":"Hope","year":"2024","journal-title":"J Nuc Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib70","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1097\/RLU.0000000000006186","article-title":"Exploring the diagnostic utility of 68 Ga-FAPI-46 PET\/CT in diverse pulmonary pathologies : a comparative analysis with 18 F-FDG PET\/CT","volume":"51","author":"Purohit","year":"2026","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2024.1360710","article-title":"Advances and challenges in immunoPET methodology","volume":"4","author":"Mohr","year":"2024","journal-title":"Front Nucl Med"},{"key":"10.1016\/j.cpet.2026.06.005_bib72","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: concept, design, and applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem Rev"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859826000581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859826000581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:31:55Z","timestamp":1785324715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859826000581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":72,"alternative-id":["S1556859826000581"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2026.06.005","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[18F]FDG-PET in Lung Cancer: From Staging to Therapy Response","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2026.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}